Additional file 2: Figure S2. of Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

Body weight of animals treated with vehicle (CTR,-♦-), with Bevacizumab and MEK162 (BEV/MEK,-■-), paclitaxel and MEK162 (PTX/MEK,-▲-), paclitaxel and bevacizumab (PTX/BEV, -●-), or paclitaxel and bevacizumab and MEK162 (PTX/BEV/MEK,-x-). Data are expressed as mean±SD, each group consisted of 8-10 animals. A) MNHOC124 PDX model, B) MNHOC218 PDX model and C) MNHOC239 PDX model. (PDF 474 kb)